SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics touches roof on getting FDA’s nod to manufacture Progesterone

13 Apr 2020 Evaluate

Lasa Supergenerics is locked at upper circuit limit at Rs. 36.65, up by 1.70 points or 4.86% from its previous closing of Rs. 34.95 on the BSE.

The scrip opened at Rs. 36.65 and has touched a high and low of Rs. 36.65 and Rs. 36.65 respectively. So far 750 shares were traded on the counter.

The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 49.70 on 28-Feb-2020 and a 52 week low of Rs. 9.48 on 06-Aug-2019.

Last one week high and low of the scrip stood at Rs. 36.65 and Rs. 31.50 respectively. The current market cap of the company is Rs. 142.15 crore.

The promoters holding in the company stood at 36.80%, while Institutions and Non-Institutions held 0.03% and 63.17% respectively.

Lasa Supergenerics has forayed into the hormone and steroid API segment for Human application with its approval from the Food and Drug Administration (FDA) authorities to manufacture Progesterone, a steroid hormone, at its WHO GMP certified facility at Mahad Industrial Area. The trial batches have already been carried out and the company is in good stead to start manufacturing from the current month itself.

Lasa Supergenerics is pioneer and amongst the leading players in the manufacturing of APIs in India through its catalyst chemistry expertise and fully backward integrated unit.


Lasa Supergenerics Share Price

8.47 0.33 (4.05%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×